Company intelligence / Profile preview

Hopewell Therapeutics

Cambridge [inferred from MassBio membership listing context—typical location for member companies but not directly confirmed]., Massachusetts, United Stateshopewell-tx.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Hopewell Therapeutics has developed a proprietary ttLNP platform for targeted delivery of genomic medicines. Their lead programs are in preclinical development targeting oncology indications such as Non-Hodgkin Lymphoma and Hepatocellular Carcinoma. The company recently raised $25 million in seed financing to advance these programs toward clinical trials.[4][5] No clinical results have been reported yet.

Therapeutic areas: OncologyOther
Modalities: Lipid Nanoparticles (LNPs)mRNA therapeuticsmRNA vaccinesTherapeutic vaccines[5]
Industry: Biotech

Beyond the preview

Go deeper on Hopewell Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hopewell Therapeutics.

Explore the full profile